Hypothesis

Core claim: The catalytic activity of carnitine acetyltransferase (CrAT) exhibits a robust circadian oscillation in skeletal muscle, driven by direct transcriptional regulation of the Crat gene by BMAL1:CLOCK heterodimers and modulated by NAD+-dependent SIRT1 deacetylation. With age, the amplitude of this oscillation blunts, leading to reduced acetyl‑carnitine flux during the active phase, mitochondrial acetyl‑CoA shortage, and consequent mitochondrial inertia that accelerates sarcopenia. Restoring the rhythmic CrAT signal—either by genetic enhancement of BMAL1 binding or by timed L‑carnitine supplementation aligned to the peak of endogenous CrAT activity—will rescue mitochondrial fatty‑acid oxidation and improve muscle regeneration independent of total carnitine pools.

Mechanistic rationale:

• Chromatin immunoprecipitation data show BMAL1 binding to E‑box motifs in promoters of fatty‑acid oxidation genes (1). We predict a conserved E‑box in the Crat promoter that drives rhythmic transcription.
• SIRT1, whose activity cycles with NAD+, deacetylates CrAT to increase its Vmax (4); age‑related NAD+ decline thus dampens both transcriptional and post‑translational activation.
• Loss of rhythmic CrAT reduces the shuttle’s capacity to buffer acetyl‑groups, causing acetyl‑CoA accumulation in cytosol and inhibiting pyruvate dehydrogenase, shifting metabolism toward glycolysis and promoting oxidative stress.

Testable predictions:

1. In young wild‑type mice, CrAT enzyme activity measured in isolated tibialis anterior extracts will show a ~2‑fold peak during the subjective night (active phase) and a trough during the day; this rhythm will be absent in muscle‑specific Bmal1 knockout mice.
2. Aged (24‑month) mice will retain the same phase but exhibit a 40‑60 % reduction in peak amplitude compared with young controls.
3. Pharmacological elevation of NAD+ (e.g., NMN) or SIRT1 activation (e.g., SRT1720) in aged mice will restore CrAT rhythm amplitude without altering total carnitine levels.
4. Administering L‑carnitine via intraperitoneal injection at the predicted CrAT activity peak (ZT14) will increase mitochondrial acetyl‑carnitine flux, improve palmitate‑oxidation rates, and enhance regeneration after cardiotoxin injury compared with injection at the trough (ZT2) or constant infusion.
5. Conversely, flattening the CrAT rhythm using a CRISPRi approach to block the Crat E‑box will exacerbate age‑related mitochondrial inertia and accelerate loss of grip strength, even if total carnitine is supplemented.

Falsifiability: If any of the above measurements fail to show a circadian variation in CrAT activity, or if timed L‑carnitine does not outperform untimed supplementation in improving oxidative metabolism and muscle repair, the hypothesis would be refuted.

Broader impact: Demonstrating a clock‑gated node in the carnitine shuttle would reposition circadian biology from a passive “firewall” to an active metabolic timer that directly gates substrate flux, offering a chronotherapeutic strategy to combat sarcopenia.